Thromb Haemost 1998; 79(03): 520-522
DOI: 10.1055/s-0037-1614937
Review Articles
Schattauer GmbH

Platelet cNOS Activity Is Reduced in Patients with IDDM and NIDDM

Valentino Martina
1   Dipartimento di Medicina Interna, Divisione di Endocrinologia, Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, Italy
,
Guido A. Bruno
1   Dipartimento di Medicina Interna, Divisione di Endocrinologia, Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, Italy
,
Fulvia Trucco
1   Dipartimento di Medicina Interna, Divisione di Endocrinologia, Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, Italy
,
Elena Zumpano
1   Dipartimento di Medicina Interna, Divisione di Endocrinologia, Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, Italy
,
Milena Tagliabue
1   Dipartimento di Medicina Interna, Divisione di Endocrinologia, Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, Italy
,
Cataldo Di Bisceglie
1   Dipartimento di Medicina Interna, Divisione di Endocrinologia, Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, Italy
,
Gianpiero Pescarmona
1   Dipartimento di Medicina Interna, Divisione di Endocrinologia, Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, Italy
› Author Affiliations
Further Information

Publication History

Received 03 March 1997

Accepted after resubmission 05 November 1997

Publication Date:
07 December 2017 (online)

Summary

Several studies in vitro and in vivo suggest that the nitric oxide (NO) production is impaired in diabetes mellitus. Reduced levels of NO could contribute to vascular alteration facilitating platelet-vascular wall interaction, adhesion of monocytes to endothelium, vascular smooth muscle proliferation and by decreasing endothelium-dependent vasodilation. In this study we evaluated the activity of the constitutive nitric oxide synthase (cNOS) in platelets of patients with insulin-dependent diabetes mellitus (IDDM) and with non-insulin-dependent diabetes mellitus (NIDDM). When compared to that of normal subjects, cNOS activity is significantly lower in patients with IDDM and with NIDDM (1.57 ± 0.25 vs. 0.66 ± 0.10 fmol/min/10 9 PLTs and 1.57 ± 0.25 vs. 0.67 ± 0.08, respectively; p <0.005). These data demonstrate that the platelet cNOS activity is decreased in diabetes mellitus.

 
  • References

  • 1 Stamler J, Vaccaro O, Neaton JD. The Multiple Risk Factor Intervention Trial Research Group Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.. Diabetes Care 1993; 16: 433-44.
  • 2 Colwell JA, Lopez-Virella M, Halushka PV. Pathogenesis of atherosclerosis in diabetes mellitus.. Diabetes Care 1981; 4: 121-33.
  • 3 Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor.. Prog Cardiovasc Dis 1984; 26: 373-412.
  • 4 Jensen T, Feldt-Rasmussen B, Bjerre-Knudsen J, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy.. Lancet 1989; ii: 461-3.
  • 5 Furchgott RF, Zawadzki V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.. Nature 1980; 288: 373-6.
  • 6 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release account for the biological activity of endothelium-derived relaxing factor.. Nature 1987; 327: 524-6.
  • 7 Palmer RMJ, Rees DD, Ashton DS. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation.. Biochem Bioph Res Co 1988; 153: 1251-6.
  • 8 Palmer RMJ, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells.. Biochem Bioph Res Co 1989; 158: 348-52.
  • 9 Moncada S, Radomski MW, Palmer RMJ. Endothelium derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function.. Biochem Pharmacol 1988; 37: 2495-501.
  • 10 Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.. Lancet 1987; ii: 1057-8.
  • 11 Radomski MW, Palmer RMJ, Moncada S. Characterisation of the L-argi-nine nitric oxide pathway in human platelets.. Brit J Pharmacol 1990; 98: 325-8.
  • 12 Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology.. Pharmacol Rev 1991; 43: 109-41.
  • 13 Pohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed.. Circ Res 1989; 5: 1798-803.
  • 14 Hogan JC, Lewis MJ, Henderson AH. In vivo EDRF activity influences platelets function.. Brit J Pharmacol 1988; 94: 1020-2.
  • 15 Durante W, Sen AK, Sunahara FA. Impairment of endothelium-dependent relaxation of aortae from spontaneously diabetic rats.. Brit J Pharmacol 1988; 94: 463-8.
  • 16 Abiru T, Watanabe Y, Kamata K, Miyata N, Kasuka Y. Decrease in endothelium-dependent relaxation and levels of cyclic nucleotides in aorta from rabbits with alloxan-induced diabetes.. Res Commun Chem Path 1990; 68: 13-25.
  • 17 Tesfamariam B, Jakubowski JA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2.. Am J Phys 1989; 257: H1327-H33.
  • 18 Gupta S, Sussman I, McArthur CS, Tornheim K, Cohen RA, Rudermann RB. Endothelium-dependent inhibition of Na-K ATPase activity in rabbit aorta by hyperglycemia. Possible role of endothelium-derived nitric oxide.. J Clin Invest 1992; 90: 727-32.
  • 19 Saenz de Tejada I, Goldstein I, Azadzoi K, Kane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence.. N Engl J Med 1989; 320: 1025-30.
  • 20 Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes.. J Clin Invest 1992; 90: 2548-54.
  • 21 McVeigh GE, Brennana GM, Johnston GD, McDermott BJ, McGrath LT, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus.. Diabetologia 1992; 35: 771-6.
  • 22 Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.. Circulation 1993; 88: 2510-6.
  • 23 Colwell JA, Lopez-Virella MF. A review of the development of large vessel disease in diabetes mellitus.. Am J Med 1988; 5A (85) 113-8.
  • 24 Amado JA, Salas E, Botana MA, Poveda JJ, Berrazueta JR. Low levels of intraplatelet cGMP in IDDM.. Diabetes Care 1993; 16: 809-11.
  • 25 Zentay Z, Raguwanshi M, Reddi A, Dasmahapatra A, Aviv A. Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM.. J Diabetes Complications 1995; 9 (02) 74-80.
  • 26 Okorodudu AO, Adegboyega PA, Scolz CL. Intracellular calcium and idrogen ions in diabetes mellitus.. Ann Clin Lab Sci 1995; 25 (05) 394-401.
  • 27 Tesfamarian B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C.. J Clin Invest 1991; 87: 1647-8.
  • 28 Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D, Stewart DJ. Lack of role for nitric oxide (NO) in the selective destabilization of endothelial NO synthase mRNA by tumor necrosis factor-α.. Arterioscl Throm Vas 1995; 15: 52-7.
  • 29 Martina V, Tagliabue M, Zumpano E, Trucco F, Stella S, Pannocchia A, Pescarmona GP. Administration of glutathione in patients with NIDDM is able to improve the intraplatelet cNOS and to decrease PAI-1.. J Endocrinol Invest 1996; 19 (Suppl. 05) 67.
  • 30 Auwerx J, Bouillo R, Collen D, Geboers D. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.. Atherosclerosis 1988; 8: 68-72.
  • 31 Martina V, Bruno GA, Pannocchia A, Zumpano E, Tagliabue M, Trucco F, Giorgiani A, Stella S, Pescarmona GP. PAI-1 reduction after treatment with glutathione in NIDDM.. Fibrinolysis 1996; 10 (Suppl. 02) 63-5.